EML4-ALK fusion gene in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate that is a threat to human health. With the development of molecular targeted research, breakthroughs have been made on the molecular mechanism of lung cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is one of the most important pathogenic driver genes of NSCLC discovered thus far. Four generations of targeted drugs for EML4-ALK have been developed, with patients benefiting significantly from these drugs. Therefore, EML4-ALK has become a research hotspot in NSCLC. The aim of the present study is to introduce the current research progress of EML4-ALK and its association with NSCLC.

Automated summary

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate, and the EML4-ALK fusion gene is one of the most important pathogenic driver genes of NSCLC. With the development of molecular targeted research, the introduction of four generations of targeted drugs for EML4-ALK has significantly benefited patients.